Moroney and McKay posted identical 3-over-par 75s while Hoodicoff shot a 77.Braden McKay of Rossland/Trail and Shawn Ellard of Kaslo finished the first day with 82s.At Balfour the players battled throughout the day with Moroney needing to play well on all 18 holes to secure the victory.Ryan Fullerton took the honors for most improved in the 15 – 18 year division and Dugan McInnes from Nakusp won most improved in the 14 and under division. With his Tour Championships title Moroney earned Player of the Year honours.Hoodikoff was top player in the 17-18 year division while Tyler McKay bested the 15-16 year old division and Braden McKay the 14 and under category.EXTRA HOLE: MacKenzie Field of Christina Lake has accepted a scholarship to play golf next year at Simon Fraser University in Burnaby while Jordan Hoodikoff is slated to tee it up south of the border at a college in Scottsdale Arizona. Many players will be representing the region in the summer games and other BCGA events as well as some events in the USA this summer. Good luck to all the kids. Brenan Moroney of Rossland/Trail needed all 36 holes to squeak out a one-stroke victory to capture the Zone One West Kootenay Junior golf title Sunday at the Balfour course.Moroney shot a 4-over-par 76 to edge Tyler McKay of Rossland/Trail and Jordan Hoodikoff of Christina Lake for the crown at the Tour Championship tournament.Saturday golfers flocked to Kokanee Springs for day one of the 36-hole tourney.The trio of Hoodikoff, McKay and Moroney led the first 18-holes.
Sioux City Police are investigating an assault that sent one person to the hospital with injuries early Friday morning.Police say an unconscious male victim was found lying on the ground at 522 4th Street in the downtown area just before 1am.The victim had suffered what was described as a serious head injury.Police say a suspect left the area on foot and could not be located by responding officers.The male victim was transported to Mercy Medical Center.His identity is not being released at this time and the suspect is unknown.The incident remains under investigation.
The Prostate Cancer Foundation (PCF) hosted the 19th Annual Gala in the Hamptons at the Parrish Art Museum in Water Mill, NY during the 14th Annual Charles Evans PCF Pro-Am Tennis Tournament weekend which raised $4 million.John FogertyCredit/Copyright: Patrick McMullanFounder Michael Milken and The Gala in the Hamptons weekend hosts and sponsors welcomed guests to enjoy, engage and be entertained while helping to fund groundbreaking discoveries in cancer research. This year’s entertainment was provided by Grammy award winning musician John Fogerty.Notable attendees included: Michael Milken (Founder), Dr. Jonathan Simons, Plum Simons, Senator Lindsey Graham, U.S. Secretary of Treasury Steven Mnuchin, Bonnie Pfeifer Evans, John Fogerty, Richard Merkin, Nick Bollettieri, Robert Citrone, Joel Pashcow, Tom and Ann Tenenbaum Lee, Glenn Myles, Jennifer Myles, Mitch Modell of Modell’s Sporting Goods, Carissa Kranz, Jason Rabin, Nicole Rabin, Igor Tulchinsky and Valentina Pavlenko, George Walker, Nancy Walker, Scott Lipsky, Daniel Nestor, Natasha Nestor, Alex Bogomolov Jr., Luana Bogomolov, Cyril Saulnier, Scott Davis, Shelly Davis, Graydon Oliver, Rick Leach, Alyssa Leach, Amer Delić, Santiago Gonzalez, Chris Haggard, Georgy Chukhleb, Ashley Fisher, Treat Huey, Robert Kendrick, Jared Palmer, John Lloyd, Jason Pinsky, Wayne Ferreira, Adam Finerman, Ralph Finerman, Bill Miller, Linda Miller, Chantelle Boulle, Anthony Boulle, David Rabin, Nicki Rabin, Heba Aberdin, Suhail Khalib, Fabrice Martin, Graydon Oliver, Natasha Oliver, Seth Bernstein, Maria Bernstein, Jay Bernstein, Allison Bernstein, Jonathan Schneider, Krista Johnson, Don Johnson, Larry Leeds, Patty Manoff, Mark Manoff and Richard Merkin.Opening the evening’s benefit dinner, Michael Milken asked a series of icebreaking questions covering topics about the weekend’s festivities which created a relaxed atmosphere and gradually eased attendees into the evening ahead of them. He followed with a special thank you to guests for their consistent support and commitment to the Prostate Cancer Foundation. Every year, the Charles Evans PCF Pro-Am Tennis Tournament raises awareness of prostate cancer and supports the foundation’s efforts to eradicate the disease that strikes one in nine American men. Over the past 14 years, the tennis tournament has raised $29 million to fund the PCF’s scientific research, while providing amateur players an invaluable experience playing alongside well-known tennis professionals. PCF Tennis Director Anthony Boulle welcomed legendary tennis coach Nick Bollettieri to the stage to reflect on his remarkable career training Serena and Venus Williams, Maria Sharapova, Boris Becker and more.In a speech paying tribute to the late Senator John McCain, who recently passed from an aggressive form of brain cancer–glioblastoma–Milken expressed the importance of raising money to fund cancer research. The Prostate Cancer Foundation has made it possible to identify drivers behind various types of cancers outside of prostate. Specializing in early stage research, PCF has also advanced brain, bladder, lung and breast cancer research.PCF’s President and Chief Executive Officer Dr. Jonathan W. Simons touched on the progress made through their life-changing research. For instance, the chances of dying and suffering of prostate cancer has reduced dramatically by 50%. The PCF Young Investigators program has identified an impactful group of future research leaders who will bring new ideas that will move the field of prostate cancer research forward. Since it’s inception in 2008, the Young Investigators Award recipients have researched 10 FDA approved treatments. Longtime supporter of PCF, CEO Mitch Modell of Modell Sporting Goods, shared that his connection to the grave disease stems from the battle a family member endured. Modell donated $101,055 in support of the Prostate Cancer Foundation.The 2018 Pro-Am Invitational weekend began on Friday, August 24th with a dinner reception hosted at the private estate of Marc Leder. The first three rounds of the tennis tournament took place on Saturday morning, August 25th, 2018 on the private courts of Bill Ackman, Michael & Margie Loeb, Josh & Marjorie Harris, John & Jenny Paulson, Jane Lauder & Kevin Warsh, George Walker, Tom & Ann Tenenbaum Lee and Leon & Debra Black. Prior to Saturday’s cocktail reception, Michael and Margie Loeb hosted a luncheon at their Southampton, NY estate in celebration of the Gala in the Hamptons. The Shinnecock Tennis Club provided the tournament site for the final rounds of the pro-am matches on Sunday. The round robin tournament, played over two days, pairs 32 amateur tennis players with a current or former member of the Association of Tennis Professionals (ATP), which includes many of the top ranked doubles players or a tennis legend.The 14th Annual Charles Evans PCF Pro-Am Tennis Tournament champions included Mark Ein with Fabrice Martin in Group 1, Chris Oberbeck with Alex Bogomolov in Group 2, Amy Griffin with Jared Palmer in Group 3 and Bob Hogan with Graydon Oliver in Group 4.Every year, the Gala in the Hamptons encourages support from organization members and tennis professionals plus amateur athletes. Celebrating everyone’s efforts, Grammy award winning musician John Fogerty performed at the lavish dinner party and ended the night in high spirits on the dance floor.The 2018 tennis professionals included: Treat Huey, Edouard Roger-Vasselin, Scott Lipsky, Daniel Nestor, Alex Bogomolov Jr., Don Johnson, Cyril Saulnier, Robert Kendrick, Vince Spadea, Scott Davis, Graydon Oliver, Jared Palmer, Rick Leach, Amer Delic, Santiago Gonzalez, John Lloyd, Jason Pinsky, Chris Haggard, Wayne Ferreira, Georgy Chukhleb, Luke Jensen and Ashley Fisher.The Prostate Cancer Foundation, founded in 1993, is dedicated to discovering groundbreaking cancer research programs thanks to the steadfast commitment from the organization, research scientists and supporters. Weekend hosts and sponsors of the 2018 Charles Evans PCF Pro-Am Tournament & Gala in the Hamptons include: Michael and Lori Milken, Bill Ackman, Steve and Alexandra Cohen, Bonnie Pfeifer Evans, Larry Gagosian and Chrissie Erpf, Joshua and Marjorie Harris, Jane Lauder and Kevin Warsh, Tom and Ann Tenenbaum Lee, Marc Leder, Richard and Karen LeFrak, Michael and Margie Loeb, William and Phyllis Mack, Richard Merkin, Modell’s Sporting Goods, Glenn and Jennifer Myles, Joel Pashcow, John and Jenny Paulson, Artie Rabin, Cliff and Barbara Sobel, Igor Tulchinsky and Valentina Pavlenko, George and Nancy Walke and Whispering Angel Wines.
For the Juventus midfielder his team is doing well in all competitions and has also said Ronaldo deserves the Ballon d’OrFor Juventus midfielder Blaise Matuidi the team is having a spectacular season in both the Italian Lega Serie A and the UEFA Champions League.“In Champions League we are doing well, we had some good matches and we only stopped against Manchester United because we did not score as many goals as we should,” Matuidi was quoted by Calcio Mercato.“Now we want to close the group in the first place, we are confident and focused, we have to play only with the Young Boys to reach the first place even if we know we will have to watch the other match”.Fiorentina owner: “Ribery played better than Ronaldo!” Andrew Smyth – September 14, 2019 Fiorentina owner Rocco Commisso was left gushing over Franck Ribery’s performance against Juventus, which he rates above that of even Cristiano Ronaldo’s.“We will have time to see what happens then, we are ambitious, but we must proceed step by step,” he added.“Fiorentina has quality, it will be a difficult game, they are a strong team at home, we know there is a rivalry between the two teams, we absolutely want to win.”“Cristiano Ronaldo deserves to win it. He always wants to win and that makes the difference,” he concluded talking about his teammate.
Bringing life to a mundane Monday morning was Priyanka Nijhawan’s inauguration of solo paintings exhibition – “The Power of Affirmation”. The artist’s idea to bring her beautiful writings of poetry to canvas through her brush was seen. The exhibition was attended by Sunil Sethi, FDCI President, Anil Sharma, Director and Producer of Indian Film Fraternity and President of India’s Grand-daughter as the guest of honor. Among other popular faces were author and socialist Ratan Kaul. Also Read – Add new books to your shelfPresident FDCI, Sunil Sethi mentioned that the artist has used the power of eyes to beautifully depict the stories of women. While the artist Priyanka says, “I want to leave a message to every woman – just be who you are, practice affirming to yourself for what you wish to achieve. The power is just inside you. The poetry in my paintings are part of those positive thoughts that I have come across while affirming. It’s the power of your subconscious. This gave me a thought that instead of painting the pain in me, I should portray the immense power that we possess. Believe me, it’s magical! Just start thinking for it and you will have it. Also Read – Over 2 hours screen time daily will make your kids impulsiveIf you will realize the power of your thoughts, you will never let in any negative thoughts.”An artist of Indian origin, Priyanka’s work reflects the inequality and sufferings of the people which she always observed in her surroundings. While her work with pencil colours is an eye catcher, Priyanka often paints on canvas with bright acrylic colours. She has taken part in various prestigious group exhibitions and solo shows. From her work, she aspires to create awareness and do her bit in making the social environment more humane and less vulnerable.You can visit the exhibition till February 10 at the Open Palm Court, India Habitat Centre from 10am to 7pm.
Does the FDA think you’re too stupid to have access to your own genetic information? It sure seems so. The Food and Drug Administration, which bills itself as “the oldest comprehensive consumer protection agency in the US federal government,” probably stirs up more emotion among citizens than any other federal agency (save perhaps for the IRS). For good reason. The range of activities into which the FDA is “mandated” to poke its supervisory fingers is vast and includes most prominently the regulation of most types of foods, dietary supplements, medical devices, human and veterinary drugs, vaccines and other biological products, and cosmetics. And this time it’s really gone too far. On November 22, 2013 the FDA sent a warning letter to the well-known consumer genomics company 23andMe ordering it to “immediately discontinue marketing” its only product. For those of you who are not familiar with 23andMe, the company provides a “DNA Spit Kit” and “Personal Genome Service” (PGS) that supposedly reports on 240+ health conditions and traits and helps clients track their ancestral lineage. Basically, you send a saliva sample in via the “Spit Kit,” and the company analyzes the sample using a DNA sequencing machine. It doesn’t give you a full readout of your genome, but tests for a custom panel of what are called single nucleotide polymorphisms in order to determine, for instance, if you’re a carrier for certain disease-linked mutations like cystic fibrosis or sickle cell anemia. The panel also tests for the three most common BRCA1 and 2 mutations that are associated with breast cancer, among many other mutations associated with other diseases. So what we’re talking about here with 23andMe is information, not a medical device. It’s your personal genetic information. And the FDA wants to put the kibosh on one of the only companies providing this service inexpensively—you get your Spit Kit and readout for just $99—to consumers. This is really a first amendment issue, and the FDA should not be in the business of regulating freedom of speech and information. But considering what the FDA thinks of your intelligence, I’m not surprised they’re trying to reach this far. Consider some of the language from the FDA’s warning letter to 23andMe. “For instance, if the BRCA-related risk assessment for breast or ovarian cancer reports a false positive, it could lead a patient to undergo prophylactic surgery, chemoprevention, intensive screening, or other morbidity-inducing actions, while a false negative could result in a failure to recognize an actual risk that may exist.” Really? You think that if a woman receives news from a $99 test that she may be at a higher risk for breast cancer due to a genetic mutation that she’s going to run out and somehow acquire chemo drugs and start dosing herself, or that she’s going to go to some back-alley clinic to have her breasts lopped off? Not to be crude or make light of a very serious situation and condition, but the FDA’s implication is insulting, to say the least. What would actually happen in the real world is that she’d go to a doctor to get herself checked out, perhaps sooner rather than later, which isn’t a bad thing even if the 23andMe test showed a false positive. Now, if the test showed a positive for the mutation and she is in fact positive—which would have to be confirmed by a separate test from a doctor anyway before a mastectomy—it is her right to undergo such surgery whether or not it is determined to be “medically necessary.” This is precisely what Angelina Jolie recently did. The false negative argument is maybe a little more plausible, but despite what the FDA might believe, people who are proactive enough about their genetic makeup in the first place to seek out a service like the PGS from 23andMe are smart. They know that no test is foolproof or 100% accurate. People receive false negative tests from federally regulated labs and physicians all the time. It’s unfortunate, but that’s the way these things work. You don’t see anybody making a stink that these tests shouldn’t be run just because there’s a small chance of delivering a patient a false negative result. In response to the FDA’s warning letter, 23andMe has stopped all TV, radio, and online advertising for its PGS, although the service is still being sold on the website. The situation is still unfolding, so whether or not the FDA decides that the company is now in compliance because it’s no longer “marketing” the PGS remains to be seen. It could determine that just having the website active is a form of “marketing,” which could be the nail in the coffin for the company. We’ll have to see. According to the FDA, 23andMe had 15 working days (starting November 22) to notify it of the specific actions the company has taken to address all of the issues raised in the letter. As expected, an additional consequence of the FDA’s warning letter is a class action lawsuit that was filed just five days after the letter was sent. The lawsuit alleges that the test results are “meaningless,” and that 23andMe uses false and misleading advertising to promote its services to US consumers. The lawsuit seeks at least $5 million under various California state laws and estimates “tens or hundreds of thousands” of US customers are entitled to damages from the company. Look, I get that many of you probably think the FDA had every right to do what it did. And I’ll admit that its actions probably were legally justified, since 23andMe’s advertising campaign did seem to market the PGS “for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease”, which falls under the FDA’s purview. I also understand why detractors of consumer genomics companies think the FDA should shut down 23andMe and all its peers/competitors—because people engaging the services of these companies don’t get the full picture, and what’s going on is much more complex. Only part of a person’s DNA is tested, and how to properly interpret the results is still uncertain, since many factors other than a mutation in isolation contribute to disease. But when do we ever get the full picture? Even a readout of our entire genome is only a small part of the story. A key takeaway from what’s known as the ENCODE Project is that much of what was previously thought of as “junk DNA” actually performs regulatory functions—which can be thought of as regions that act like switches attached to a particular gene which determine whether or not they’ll be expressed. There are millions of such regions throughout the genome, and they’re linked to each other (and to the protein-coding genes) in an extremely complicated hierarchical network. What’s more, the linear ordering of the genome provides a further source of confusion: the three-dimensional folding of the chromosomes inside the nucleus allows promoter regions to maintain a close connection to genes that apparently lie far away on the linear sequence. This explains why so much biochemical activity can be found even deep in the deserts of the alleged “junk DNA.” Many of these promoter regions manifest themselves in the cell as “functional RNA” molecules—types of RNA that are an end product in themselves, rather than merely an intermediate step on the way to becoming a protein, and which play a key role in switching genes on and off. In truth, we never get the full story, no matter whom we turn to, and there’s nothing wrong with bits and pieces of information to help us make decisions along the way (or just to satisfy our curious nature). And that’s really the whole point here. I don’t really care if what the FDA did was technically legal or that some people think it makes sense in order to keep others from harming themselves in some way. What matters is that this ultimately boils down to information—personal genetic information. And whether 23andMe does a good job of providing that or not, it’s our right to seek out such a service and use it if we so desire.